Hepatitis C Virus Double-Stranded RNA Is the Predominant Form in Human Liver and in Interferon-Treated Cells

被引:11
作者
Klepper, Arielle [1 ]
Eng, Francis J. [1 ]
Doyle, Erin H. [1 ]
El-Shamy, Ahmed [1 ]
Rahman, Adeeb H. [1 ]
Fiel, M. Isabel [1 ]
Avino, Gonzalo Carrasco [1 ]
Lee, Moonju [1 ]
Ye, Fei [1 ]
Roayaie, Sasan [1 ]
Bansal, Meena B. [1 ]
MacDonald, Margaret R. [2 ]
Schiano, Thomas D. [1 ]
Branch, Andrea D. [1 ]
机构
[1] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[2] Rockefeller Univ, Lab Virol & Infect Dis, 1230 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
SUSTAINED VIROLOGICAL RESPONSE; GENETIC-VARIATION; VIRAL CLEARANCE; ADAPTER PROTEIN; REPLICATION; INFECTION; HCV; PERSISTENCE; EXPRESSION; RIBAVIRIN;
D O I
10.1002/hep.28846
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Hepatitis C virus (HCV) is unique among RNA viruses in its ability to establish chronic infection in the majority of exposed adults. HCV persists in the liver despite interferon (IFN)-stimulated gene (ISG) induction; robust induction actually predicts treatment failure and viral persistence. It is unclear which forms of HCV RNA are associated with ISG induction and IFN resistance during natural infections. To thoroughly delineate HCV RNA populations, we developed conditions that fully separate the strands of long double-stranded RNA (dsRNA) and allow the released RNAs to be quantified in reverse transcription/ polymerase chain reaction assays. These methods revealed that dsRNA, a pathogen-associated molecular pattern (PAMP), comprised 52% (standard deviation, 28%) of the HCV RNA in the livers of patients with chronic infection. HCV dsRNA was proportionally higher in patients with the unfavorable IL28B TT (rs12979860) genotype. Higher ratios of HCV double-stranded to single-stranded RNA (ssRNA) correlated positively with ISG induction. In Huh-7.5 cells, IFN treatment increased the total amount of HCV dsRNA through a process that required de novo viral RNA synthesis and shifted the ratio of viral dsRNA/ssRNA in favor of dsRNA. This shift was blocked by ribavirin (RBV), an antiviral drug that reduces relapse in HCV patients. Northern blotting established that HCV dsRNA contained genome-length minus strands. Conclusion: HCV dsRNA is the predominant form in the HCV-infected liver and has features of both a PAMP and a genomic reservoir. Interferon treatment increased rather than decreased HCV dsRNA. This unexpected finding suggests that HCV produces dsRNA in response to IFN, potentially to antagonize antiviral defenses.
引用
收藏
页码:357 / 370
页数:14
相关论文
共 45 条
  • [1] Persistence of HCV in Quiescent Hepatic Cells Under Conditions of an Interferon-Induced Antiviral Response
    Bauhofer, Oliver
    Ruggieri, Alessia
    Schmid, Bianca
    Schirmacher, Peter
    Bartenschlager, Ralf
    [J]. GASTROENTEROLOGY, 2012, 143 (02) : 429 - +
  • [2] Costs of Telaprevir-Based Triple Therapy for Hepatitis C: $189,000 Per Sustained Virological Response
    Bichoupan, Kian
    Martel-Laferriere, Valerie
    Sachs, David
    Ng, Michel
    Schonfeld, Emily A.
    Pappas, Alexis
    Crismale, James
    Stivala, Alicia
    Khaitova, Viktoriya
    Gardenier, Donald
    Linderman, Michael
    Perumalswami, Ponni V.
    Schiano, Thomas D.
    Odin, Joseph A.
    Liu, Lawrence
    Moskowitz, Alan J.
    Dieterich, Douglas T.
    Branch, Andrea D.
    [J]. HEPATOLOGY, 2014, 60 (04) : 1187 - 1195
  • [3] Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection
    Chen, LM
    Borozan, I
    Feld, J
    Sun, J
    Tannis, LL
    Coltescu, C
    Heathcote, J
    Edwards, AM
    McGilvray, ID
    [J]. GASTROENTEROLOGY, 2005, 128 (05) : 1437 - 1444
  • [4] Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis
    Curry, M. P.
    O'Leary, J. G.
    Bzowej, N.
    Muir, A. J.
    Korenblat, K. M.
    Fenkel, J. M.
    Reddy, K. R.
    Lawitz, E.
    Flamm, S. L.
    Schiano, T.
    Teperman, L.
    Fontana, R.
    Schiff, E.
    Fried, M.
    Doehle, B.
    An, D.
    McNally, J.
    Osinusi, A.
    Brainard, D. M.
    McHutchison, J. G.
    Brown, R. S., Jr.
    Charlton, M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (27) : 2618 - 2628
  • [5] Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
    Davis, GL
    Esteban-Mur, R
    Rustgi, V
    Hoefs, J
    Gordon, SC
    Trepo, C
    Shiffman, ML
    Zeuzem, S
    Craxi, A
    Ling, MH
    Albrecht, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (21) : 1493 - 1499
  • [6] POLIOVIRUS SINGLE-STRANDED RNA AND DOUBLE-STRANDED-RNA - DIFFERENTIAL INFECTIVITY IN ENUCLEATE CELLS
    DETJEN, BM
    LUCAS, J
    WIMMER, E
    [J]. JOURNAL OF VIROLOGY, 1978, 27 (03) : 582 - 586
  • [7] Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response
    Feld, Jordan J.
    Nanda, Santosh
    Huang, Ying
    Chen, Weiping
    Cam, Maggie
    Pusek, Susan N.
    Schweigler, Lisa M.
    Theodore, Dickens
    Zacks, Steven L.
    Liang, T. Jake
    Fried, Michael W.
    [J]. HEPATOLOGY, 2007, 46 (05) : 1548 - 1563
  • [8] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Ge, Dongliang
    Fellay, Jacques
    Thompson, Alexander J.
    Simon, Jason S.
    Shianna, Kevin V.
    Urban, Thomas J.
    Heinzen, Erin L.
    Qiu, Ping
    Bertelsen, Arthur H.
    Muir, Andrew J.
    Sulkowski, Mark
    McHutchison, John G.
    Goldstein, David B.
    [J]. NATURE, 2009, 461 (7262) : 399 - 401
  • [9] SECONDARY STRUCTURE OF REOVIRUS RNA
    GOMATOS, PJ
    TAMM, I
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1963, 49 (05) : 707 - &
  • [10] Effect of alpha interferon on the hepatitis C virus replicon
    Guo, JT
    Bichko, VV
    Seeger, C
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (18) : 8516 - 8523